An eighth product candidate in our generics pipeline is desvenlafaxine extended-release tablets. It is a generic version of the marketed drug Pristiq®. This product is currently the subject of an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA) and is partnered with Mallinckrodt LLC ("Mallinckrodt"). In October 2016, the Company also announced it had entered into a license and commercial supply agreement with Mallinckrodt, by which the Company has granted Mallinckrodt an exclusive license to market, sell and distribute in the United States its ANDA for generic Pristiq® under a 10 year agreement.
Desvenlafaxine is a selective serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder. According to Symphony Health Solutions, U.S. sales for the 12 months ending January 2017 for Pristiq® were approximately $889 million (TRx MBS Dollars).